Artwork

Contenido proporcionado por The Ringer. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente The Ringer o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !

Are GLP-1 Drugs "the Greatest Medical Breakthrough of the 21st Century"?

1:04:13
 
Compartir
 

Manage episode 464193198 series 3008690
Contenido proporcionado por The Ringer. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente The Ringer o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

In the past few years, we've learned that GLP-1 drugs don’t just help with diabetes or increase people’s feelings of fullness to help them lose weight. They have broad effects on substance abuse and behavior. They even seem to help with otherwise incurable illnesses, like Alzheimer's and schizophrenia. This month, a team of scientists studying 2 million patients in the Veterans Affairs medical system found that GLP-1s were associated with “a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders (clotting), cardiometabolic disorders (like strokes and heart attacks), infectious illnesses and several respiratory conditions.”

Today’s guest is a coauthor on the paper, Ziyad Al-Aly. He is a physician-scientist at Washington University in St. Louis. We talk about his new paper, the steps he took to make sure his findings were trustworthy, why GLP-1 drugs might work so well, what they’re teaching us about the brain and body, how they’re scrambling our sense of where volition begins and where free will ends, and what scientists should do next with the revelation that these drugs have effects that go far beyond obesity and diabetes.

If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com.

Host: Derek Thompson

Guest: Ziyad Al-Aly

Producer: Devon Baroldi

Links:

  • Al-Aly et al. on the effectiveness and risks of GLP-1 drugs [link]

Learn more about your ad choices. Visit podcastchoices.com/adchoices

  continue reading

277 episodios

Artwork
iconCompartir
 
Manage episode 464193198 series 3008690
Contenido proporcionado por The Ringer. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente The Ringer o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

In the past few years, we've learned that GLP-1 drugs don’t just help with diabetes or increase people’s feelings of fullness to help them lose weight. They have broad effects on substance abuse and behavior. They even seem to help with otherwise incurable illnesses, like Alzheimer's and schizophrenia. This month, a team of scientists studying 2 million patients in the Veterans Affairs medical system found that GLP-1s were associated with “a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders (clotting), cardiometabolic disorders (like strokes and heart attacks), infectious illnesses and several respiratory conditions.”

Today’s guest is a coauthor on the paper, Ziyad Al-Aly. He is a physician-scientist at Washington University in St. Louis. We talk about his new paper, the steps he took to make sure his findings were trustworthy, why GLP-1 drugs might work so well, what they’re teaching us about the brain and body, how they’re scrambling our sense of where volition begins and where free will ends, and what scientists should do next with the revelation that these drugs have effects that go far beyond obesity and diabetes.

If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com.

Host: Derek Thompson

Guest: Ziyad Al-Aly

Producer: Devon Baroldi

Links:

  • Al-Aly et al. on the effectiveness and risks of GLP-1 drugs [link]

Learn more about your ad choices. Visit podcastchoices.com/adchoices

  continue reading

277 episodios

Todos los episodios

×
 
Loading …

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

 

Guia de referencia rapida

Escucha este programa mientras exploras
Reproducir